Navigating China’s Market Access Landscape
Strategic Decision-Making in a Multi-Layer Coverage Environment
Overview
China’s market access system is undergoing structural transition. While the NRDL remains central, emerging commercial mechanisms and policy experimentation are reshaping how innovation is funded and sequenced across payment layers.
This masterclass is designed as a structured strategic foundation for global and China life sciences leaders. It clarifies how China’s evolving multi-layer coverage framework operates in practice and integrates the most up-to-date policy intelligence to recalibrate how China access decisions are assessed across functions and leadership levels.
Through structured interpretation and guided case application, participants connect system-level signals to real-world strategic trade-offs. The program sharpens how organizations evaluate decision inflection points, implementation risks, and execution constraints embedded within China’s evolving coverage landscape.
Who This Is For
This masterclass is designed for decision-makers shaping China strategy across market access, policy, commercial planning, business development, and investment evaluation.
Participants typically include:
- Global pricing and market access leaders
- Regional and China market access heads
- Commercial and portfolio strategy executives
- Policy and external affairs executives
- Business development and corporate strategy professionals evaluating China opportunity
- Investment professionals assessing China-related life sciences exposure
- Consulting leaders advising life sciences clients on China strategy
Format
Delivered as a structured three-session cohort experience over three weeks:
- Session 1: Access Landscape & Strategic Implications (Live)
- Session 2: Self-Reflection & Intelligence Integration + Required Question Submission
- Session 3: Case-Anchored Strategic Integration & Q&A (Live)
Between the two live sessions, participants engage in structured reflection and submit at least one substantive question to inform the case-driven integration discussion.
Participants receive three-month access to session recordings and curated Access360 readings for continued reference.
Enrollment is limited to preserve discussion quality.
Session 1 — Access Landscape & Strategic Implications (Live)
A high-density executive briefing establishing a coherent framework for evaluating China’s evolving multi-layer coverage and financing system, and the latest policy signals shaping commercialization decisions across innovative medicines.
The session provides structured lenses for interpreting policy and implementation dynamics across basic insurance, commercial coverage, and pricing governance— enabling more disciplined assessment of strategic options.
Session 2 — Self-Reflection & Intelligence Integration
Participants review the Session 1 recording alongside curated Access360 intelligence pieces that expand on the most consequential developments shaping China’s access environment.
This reflection phase is designed to:
- Strengthen evaluation of the strategic levers shaping China’s pricing, reimbursement, and access landscape for any medical technologies
- Connect evolving policy signals to broader strategic implications
- Surface blind spots and questions critical for shaping China access strategies
Participants must submit at least one substantive question in advance of Session 3. Questions should aim to sharpen strategic thinking and decision framing as China’s access environment continues to evolve.
Session 3 — Case-Anchored Strategic Integration & Q&A (Live)
An interactive live session designed to guide participants through the most critical strategic questions emerging as China’s multi-layer coverage dynamics reshape market access decisions.
Using a structured case vignette, participants work through a disciplined sequence of decision questions that clarify strategic trade-offs, identify key inflection points, and surface implementation risks and execution constraints embedded within evolving coverage dynamics.
The case discussion establishes a foundational layer for asset-specific and portfolio-level strategy development.
A dedicated segment then addresses participant pre-submitted questions, providing additional strategic clarification across diverse decision contexts.
This applied integration session is consistently highlighted by participants as one of the most valuable components of the program for sharpening strategic framing and strengthening decision confidence.
Executive & Academic Perspectives
“The timing is perfect, as it coincides with what may be a significant shift in how high-value medicines enter the Chinese market. The program allowed me to track developments in real time, with monitoring and analysis that highlighted both opportunities and remaining uncertainties. All in all, I would not have had it any other way—well done.”
— Director Access Policy, Top 10 Pharma
“It provided us with a comprehensive overview of China’s multi-layer healthcare system, along with inspiring questions and takeaways that are valuable for our strategy development.”
— Head China Market Access, Top Specialty Pharma
“It’s difficult to conduct desk research on China’s reimbursement policy changes, so the Masterclass provided a clear and structured way to access information in English. The session was insightful and highly valuable.”
— Head Global Market Access, Top Specialty Pharma
"The discussion on the C-List and NRDL was truly enlightening from a future physician’s perspective. I really appreciated how thorough and deliberate the lecture was—each slide was meaningful and tied to a clear learning goal. The most impactful part of the lecture was how it addressed the questions we prepared beforehand. It really connected the lecture content with the preconceived ideas we had going in. I learned so much in such a short time.”
— Graduate Student, University of Southern California
“The case vignette was very helpful in applying the framework to a real situation. It pushed me to think more strategically about the various market access considerations and helped bridge the transition from understanding the concepts to thinking about implementation.”
— Graduate Student, University of Southern California
About the Program Lead
Kelly Ke
Founder, bizi LLC | Architect of NRDL+
Kelly Ke is the founder of bizi LLC and the architect of NRDL+, a strategic intelligence platform focused on China’s evolving coverage and financing architecture.
Prior to founding bizi LLC, Kelly spent a decade as an award-winning senior advisor in Deloitte US’s Life Sciences practice. Since then, she has led bizi’s work advising global life sciences leadership teams on pricing, reimbursement, and market access in both global and local contexts.
Her work is followed by senior leaders from over two-thirds of the world’s top 30 pharmaceutical companies, alongside executives across leading biotechs, commercial insurers, and academic institutions.
Her recent co-authored policy analysis, published in Caixin, sparked active discussion among industry stakeholders and contributed to broader national debate on China’s evolving multi-layer coverage framework and its implications for innovative medicines.
Operating at the intersection of health policy and executive decision-making, Kelly interprets evolving regulatory and implementation dynamics and translates them into actionable implications that help organizations recalibrate their China strategy.
Enrollment
Next Cohort: April 23, 2026
Enrollment closes: April 20, 2026 (three days prior to Session 1)
Live sessions: 9:00–10:00 AM U.S. Eastern Time
Cohorts are convened 2–3 times per year.
Investment: USD 4,000 per participant (plus applicable taxes)
Enrollment is intentionally limited to preserve discussion depth and engagement quality. Group participation is encouraged to support cross-functional alignment.
For company-sponsored enrollments requiring VAT reimbursement, please enter your company VAT ID during checkout.